Article Text

Download PDFPDF

151 Cardiac Myosin-Binding Protein C is a Novel Marker of Myocardial Injury and Fibrosis in Patients with Aortic Stenosis
  1. Atul Anand1,
  2. Calvin Chin2,
  3. Anoop Shah2,
  4. Jacek Kwieciński3,
  5. Alex Vesey2,
  6. Joanna Cowell4,
  7. Ekkehard Weber5,
  8. Thomas Kaier6,
  9. David Newby7,
  10. Marc Dweck7,
  11. Michael Marber6,
  12. Nicholas Mills7
  1. 1University of Edinburgh, BHF Centre for Cardiovascular Science
  2. 2University of Edinburgh
  3. 3University of Edinburgh and Poznan University of Medical Sciences
  4. 4Department of Geriatric Medicine, NHS Lothian
  5. 5Institute of Physiological Chemistry, Martin Luther University Halle-Wittenberg
  6. 6King’s College London BHF Centre
  7. 7BHF Centre for Cardiovascular Science, University of Edinburgh


Background Cardiac myosin binding protein C (cMyC) is an abundant sarcomeric protein and a novel highly specific marker of myocardial injury. Given myocyte death characterises the transition from hypertrophy to replacement myocardial fibrosis in advanced aortic stenosis, we hypothesised that serum cMyC concentrations would be associated with cardiac structure and outcomes in patients with aortic stenosis.

Methods cMyC was measured in two cohorts: a mechanism cohort of patients with aortic stenosis (n = 161) and healthy controls (n = 46) who underwent cardiac magnetic resonance imaging, and an outcomes cohort with aortic stenosis (n = 104) followed for a median of 11.3 years. Tru cut myocardial biopsies were obtained from 10 patients in the mechanism cohort who underwent aortic valve replacement. These samples underwent staining and analysis for myocyte death.

Results In the mechanism cohort, cMyC concentration correlated with left ventricular mass (r = 0.59, 95% CI 0.47–0.68, p < 0.0001), fibrosis volume (r = 0.57, 95% CI 0.45–0.67, p < 0.0001) and extracellular volume (r = 0.28, 95% CI 0.12–0.42, p = 0.0004) in patients with aortic stenosis but not in controls (Figure 1). In those with late gadolinium enhancement (LGE), cMyC was higher (32 [21–56] ng/L vs 17 [12–24] ng/L without LGE, p < 0.001). cMyC was unrelated to aortic transvalvular gradient or objective assessment of coronary disease. Unadjusted Cox proportional hazards analysis in the outcomes cohort showed greater all-cause mortality (HR 1.53 per doubling of cMyC, 95% CI 1.13–2.06, p = 0.006). In exploratory analyses, a relationship was observed between cMyC and the rate of myocyte death (expressed as the sum of apoptosis, oncosis and autophagy counts) in biopsy samples (r = 0.67, 95% CI 0.08–0.92, p = 0.03). Clear differences were observed in staining patterns for oncosis and autophagy between subjects with low and high cMyC concentrations (Figure 2).

Conclusion Serum cMyC concentration is associated with myocardial hypertrophy, fibrosis and an increased risk of mortality in aortic stenosis. The quantification of serum sarcomeric protein concentrations have major potential to provide objective measures of disease progression and to guide clinical decisions in patients with aortic stenosis.

Abstract 151 Figure 1

Linear regression correlation of cMyC with indexed LV mass and fibrosis volume in aortic stenosis

Abstract 151 Figure 2

Oncosis and autophagy in biopsy samples from patients with low and high cMyC concentrations, visualised using a 3,3’-diaminobenzidine staining. Plot shows correlation between cMyC and total myocyte death rate acros 10 patients tested

  • myosin binding protein C
  • aortic stenosis
  • biomarkers

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.